540359 PARMAX

Parmax Pharma Share Price

₹46.00 -2.25 (-4.66%)

24 Nov, 2024 01:11

SIP TrendupStart SIP in PARMAX

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 5.14%
  • Over 3 Month + 35.25%
  • Over 6 Month + 46.03%
  • Over 1 Year + 49.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹46.00
-2.25 (-4.66%)
pointer
  • stock-down_img
  • Bullish Moving Average 8
  • stock-up_img
  • Bearish Moving Average 8
  • 20 Day
  • ₹46.78
  • 50 Day
  • ₹44.08
  • 100 Day
  • ₹40.81
  • 200 Day
  • ₹37.44

Resistance and Support

46.38 Pivot Speed
  • R3 48.36
  • R2 47.83
  • R1 46.91
  • S1 45.46
  • S2 44.93
  • S3 44.01

What's your outlook on Parmax Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 22.68 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -51% needs improvement, ROE of -5458% is poor and needs improvement. The company has a high debt to equity of 5607%, which can be a reason to worry. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
62.9%
6.3%

About Parmax Pharma

  • NSE Symbol
  • PARMAX
  • BSE Symbol
  • 540359
  • Managing Director
  • Dr. Umang Alkesh Gosalia
  • ISIN
  • INE240T01014

Similar Stocks to Parmax Pharma

Parmax Pharma FAQs

Parmax Pharma share price is ₹46 As on 24 November, 2024 | 00:57

The Market Cap of Parmax Pharma is ₹17.2 Cr As on 24 November, 2024 | 00:57

The P/E ratio of Parmax Pharma is -5.1 As on 24 November, 2024 | 00:57

The PB ratio of Parmax Pharma is 163.8 As on 24 November, 2024 | 00:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23